{"filing":{"accession_number":"0001575872-26-000555","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-08-10","report_date":"2026-08-07","primary_document":"rdy0934_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000555/rdy0934_6k.htm"},"events":[{"id":26481,"run_id":24070,"accession_number":"0001575872-26-000555","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Dr. Reddy's has terminated a distribution and promotion agreement with Novartis India Limited effective September 30, 2026, triggered by a change in controlling shareholding of the counterparty. This is a material operational event affecting the company's commercialization of select brands in India, but does not fit the specific categories of M\u0026A activity, material litigation, or other named event types. The termination of a significant distribution arrangement is a strategic business event that would affect investor assessment of the company's revenue streams and market position.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27616,"accession_number":"0001575872-26-000555","item_number":"EX-99.1","item_title":"rdy0934_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's has terminated a distribution and promotion agreement with Novartis India Limited effective September 30, 2026, triggered by a change in controlling shareholding of the counterparty. This is a material operational event affecting the company's commercialization of select brands in India, but does not fit the specific categories of M\u0026A activity, material litigation, or other named event types. The termination of a significant distribution arrangement is a strategic business event that would affect investor assessment of the company's revenue streams and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T16:19:42.330600+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27616,"accession_number":"0001575872-26-000555","item_number":"EX-99.1","item_title":"rdy0934_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Dr. Reddy's has terminated a distribution and promotion agreement with Novartis India Limited effective September 30, 2026, triggered by a change in controlling shareholding of the counterparty. This is a material operational event affecting the company's commercialization of select brands in India, but does not fit the specific categories of M\u0026A activity, material litigation, or other named event types. The termination of a significant distribution arrangement is a strategic business event that would affect investor assessment of the company's revenue streams and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T16:19:42.330600+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-08-10"}]}